*Hypophosphatemic disorders are also referred to as X-Linked Hypophosphatemia, X-linked hypophosphatemic rickets, hereditary hypophosphatemic rickets, familial hypophosphatemic rickets, vitamin D-resistant rickets (VDRR), vitamin D-resistant osteomalacia, X-linked vitamin D-resistant rickets, hypophosphatemic rickets, hypophosphatemic vitamin D-resistant rickets (HPDR), genetic rickets, or familial hypophosphatemia.
The Hypophosphatemia program offers testing with the Invitae Hypophosphatemia Panel
The Invitae Hypophosphatemia Panel includes genes known to be associated with hypophosphatemia: ALPL, CLCN5, CTNS, CYP2R1, CYP27B1, DMP1, ENPP1, FAH, FAM20C, FGF23, FGFR1, GNAS, OCRL, PHEX, SLC34A1, SLC34A3 and VDR. Once Invitae receives the sample, your results will be available in 10 to 21 calendar days on average.View panel
If a positive result is identified, testing for your patient’s family members is available.
Simply follow the ordering instructions, selecting only the gene(s) you are interested in testing for the family member. The partner code will automatically be added with the order.
Available to answer your questions or help you through the testing process.CONTACT
Regardless of test result, Ultragenyx is sponsoring no-charge, telephone-based genetic counseling for patients tested through the program in the US. For assistance with genetic counseling or to schedule an appointment, please call InformedDNA, the third-party genetic counseling service, at 888-744-8952.
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.
While Ultragenyx provides financial support for this program, the genetic testing and counseling services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program and shall not seek reimbursement for the testing or services provided under this program from any third party, including but not limited to federal healthcare programs. Ultragenyx receives de-identified patient data from this program, but at no time does Ultragenyx receive patient identifiable information. Ultragenyx receives contact information for healthcare professionals who use this program. Genetic testing and counseling services are available in the US only. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Ultragenyx product.